首页> 美国卫生研究院文献>Aging (Albany NY) >Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma
【2h】

Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma

机译:鉴定在早期和晚期结肠腺癌中编码肿瘤特异性新稻草的候选基因

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colon adenocarcinoma (COAD) is one of the most common gastrointestinal malignant tumors and is characterized by a high mortality rate. Here, we integrated whole-exome and RNA sequencing data from The Cancer Genome Atlas and investigated the mutational spectra of COAD-overexpressed genes to define clinically relevant diagnostic/prognostic signatures and to unmask functional relationships with both tumor-infiltrating immune cells and regulatory miRNAs. We identified 24 recurrently mutated genes (frequency > 5%) encoding putative COAD-specific neoantigens. Five of them (NEB, DNAH2, ABCA12, CENPF and CELSR1) had not been previously reported as COAD biomarkers. Through machine learning-based feature selection, four early-stage-related (COL11A1, TG, SOX9, and DNAH2) and four late-stage-related (COL11A1, SOX9, TG and BRCA2) candidate neoantigen-encoding genes were selected as diagnostic signatures. They respectively showed 100% and 97% accuracy in predicting early- and late-stage patients, and an 8-gene signature had excellent prognostic performance predicting disease-free survival (DFS) in COAD patients. We also found significant correlations between the 24 candidate neoantigen genes and the abundance and/or activation status of 22 tumor-infiltrating immune cell types and 56 regulatory miRNAs. Our novel neoantigen-based signatures may improve diagnostic and prognostic accuracy and help design targeted immunotherapies for COAD treatment.
机译:结肠腺癌(Coad)是最常见的胃肠道恶性肿瘤之一,其特征在于死亡率高。在此,我们从癌症基因组地图集综合整体和RNA测序数据,并研究了共同抑制基因的突变光谱,以定义临床相关的诊断/预后签名并与肿瘤浸润的免疫细胞和调节miRNA揭开功能关系。我们鉴定了24个常静的基因(频率> 5%)编码推定的辅助特异性新奥地利古代。其中五个(NEB,DNAH2,ABCA12,CENPF和CELSR1)以前尚未称为Coad Biomarkers。通过基于机器学习的特征选择,选择四种与早期相关的(COL11A1,TG,SOX9和DNAH2)和四个相关的(COL11A1,SOX9,TG和BRCA2)候选新尼奥编码基因被选择为诊断签名。它们分别显示出预测早期和晚期患者的100%和97%的准确性,8-基因签名具有预测Coad患者的无病生存(DFS)的优异预后性能。我们还发现24个候选新宿老基因与22种肿瘤浸润免疫细胞类型和56个调节miRNA的丰富和/或活化状态之间的显着相关性。我们的新新型新奥根根签名可以改善诊断和预后的准确性,帮助设计有针对性的Coad治疗的免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号